ArticleJournal of proteome research2026
Proteomic Analysis of Paired FFPE Tissue and Extracellular Vesicles Reveals Proteins Associated with Recurrence in Stage II Colorectal Cancer.
Article in Journal of proteome research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) remains a leading cause of cancer-related mortality worldwide. Stage II CRC poses a clinical challenge due to its heterogeneous outcomes, with 15-20% of patients experiencing recurrence. Current prognostic models based on clinicopathologic features lack sufficient precision, highlighting the need for new molecular markers. In this study, we employed an integrative TMT-based proteomics strategy to identify biomarkers of recurrence in stage II CRC. We analyzed paired formalin-fixed paraffin-embedded (FFPE) tissues and small extracellular vesicles (sEVs) from stage II recurrent and nonrecurrent CRC patients. Validation of proteomics data was performed in silico and by WB, immunohistochemistry, ELISA, and in vitro functional cell-based assays. This multifaceted approach identified several dysregulated proteins associated with CRC recurrence, including MANF, TLN1, TALDO1, and CDCA2, among others. CDCA2 knockdown altered the tumorigenic properties of CRC cells in vitro, correlating findings with its association with prognosis. Conversely, higher plasma levels of MANF were found in nonrecurrent CRC patients, aligning results with its favorable prognosis profile. Collectively, our findings support the value of combining paired FFPE tissue and sEVs proteomics analyses to uncover recurrence-associated biomarkers, offering the potential for risk stratification and management of stage II CRC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.